No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1480-1483

  Goto, Naoki ^a   Yoshimura, Reiji ^a   Kakeda, Shingo ^a   Moriya, Junji ^a   Hori, Hikaru ^a   Hayashi, Kenji ^a   Ikenouchi Sugita, Atsuko ^a   Nakano Umene, Wakako ^a   Katsuki, Asuka ^a   Nishimura, Joji ^a   Korogi, Yukunori ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Atypical antipsychotic drug; GABA; MRS; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRONTAL LOBE; GABAERGIC TRANSMISSION; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL LOBE; PARIETAL LOBE; SCHIZOPHRENIA; SHORT COURSE THERAPY; TREATMENT DURATION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649502986     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.007     Document Type: Article

References (27)

1. Akbarian S., Huang H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res Rev 2006, 52:293-304.
2. A text Revision of Diagnostic and Statistical Manual of Mental Disorder 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th edition.
3. Benes F.M., Vincent S.L., Marie A., Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 1996, 75:1021-1031.
4. Choe B.Y., Suh T.S., Shinn K.S., Lee C., Paik I.H. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydroxygen magnetic spectroscopy. Investig Radiol 1996, 31:345-352.
5. Coupland N.J., Ogilvie C.J., Hegadoren K.M., Seres P., Hanstock C.C., Allen P.S. Decreased prefrontal myoinositol in major depressive disorder. Biol Psychiatry 2005, 57:1526-1534.
6. Ernst T., Kreis R., Ross B.D. Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J Magn Reson Ser B 1993, 102:1-8.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Patient edition (SCID-P), version 2 New York State Psychiatric Institute, Biometrics Research, New York 1995.
8. Gonzalez-Burgos G., Hashimoto T., Lewis D.A. Alterations of GABA neurons and network oscillations in schizophrenia. Curr Psychiatry Rep 2010, Jun 17 [Epub ahead of print].
9. Goto N., Yoshimura R., Ueda N., Ikenouchi-Sugita A., Umene-Nakano W., et al. Reduction of brain gamma-aminobutylic acid (GABA) concentrations in early-stage schizophrenia patients: 3T proton MRS study. Schizophr Res 2009, 112:192-193.
10. Hanada S., Mita T., Tanaka C. [3H]Muscimol binding sites increased autopsied brains of chronic schizophrenics. Life Sci 1987, 40:259-266.
11. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H. Pisu MG A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998, 95:15718-15723.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
13. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
14. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005, 6:312-324.
15. Mescher M., Merkle H., Kirsh J., Garwood M., Gruetter M. Simultaneous in vivo spectral editing and water suppression. NMR Biomed 1998, 11:266-272.
16. Ongur D., Prescot A.P., Jensen J.E., Cohen B.M., Renshaw P.F. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res 2009, 172:44-48.
17. Provenhcar S.W. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993, 30:672-679.
18. Rao S.G., Williams G.V., Goldman-Rakic P.S. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. J Neurosci 2000, 20:485-494.
19. Sawaguchi T., Matsumura M., Kubota K. Delayed response deficit in monkeys by locally disturbed prefrontal neuronal activity by bicuculline. Behav Brain Res 1989, 31:193-198.
20. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-Neuropsychiatric International Interview (M.I.N.I.): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl):22-23.
21. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991, 121:77-80.
22. Simpson M.D.C., Slater P., Deakin J.F.K., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989, 107:211-215.
23. Tayoshi S.Y., Nakataki M., Sumitani S., Taniguchi K., Shibuya-Tayoshi S., Numata S., et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2010, 117:83-91.
24. Torrey E.F., Barci B.M., Webster M.J., Bartko J.J., Meador-Woodruff J.H., Knable M.B. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005, 57:252-260.
25. Van Kammen D.P., Sternberg D.E., Hare T.A., Waters R.N., Bunney W.E. CSF levels of gamma-aminobutyric acid in schizophrenia: low values in recently ill patients. Arch Gen Psychiatry 1982, 39:91-97.
26. Van Kammen D.P., Petty F., Kelley M.E., Kramer G.L., Barry E.J., Yao J.K. GABA and brain abnormalities in schizophrenia. Psychiatry Res 1998, 82:25-35.
27. Yoon J.H., Maddock R.J., Rokem A., Silver M.A., Minzenberg M.J., Ragland J.D., et al. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 2010, 30:3777-3781.